Anti-CD19 (B-Lymfocyten Marker) Monoklonale Antilichaam (Kloon: PDR134)

CD19 is a transmembrane glycoprotein that contains two extracellular immunoglobulin-like domains. CD19 is present in both benign and malignant B-cells and is considered to be the most reliable surface marker of this lineage over a wide range of maturational stages. In normal lymphoid tissue, CD19 is observed in germinal centers, in mantle zone cells, and in scattered cells of the inter-follicular areas. Anti-CD19 exhibits an overall immunoreactivity pattern similar to those of the antibodies against CD20 and CD22. However, in contrast to CD20, expression of CD19 is continuous throμghout B-cell development and throμgh terminal differentiation of B-cells into plasma cells. Anti-CD19 positivity is seen in the vast majority of B-cell neoplasms commonly at a lower intensity than normal B-cell counterparts. Plasma cell neoplasms are nearly always negative, as are T-cell neoplasms.

B-lymphocyte antigen CD19; B-lymphocyte surface antigen B4; CVID3; Leu-12; Lymphocyte Surface Antigen; T-cell surface antigen Leu-12

CD19

930

P15391

Human

Pokeweek-stimulated Daudi and Raji cells

PDR134

ELISA, FACS, IF, WB

200 μg/mL of Ab Purified from Bioreactor Concentrate by Protein A/G. Prepared in 10mM PBS with 0.05% BSA & 0.05% azide. Also available WITHOUT BSA & azide at 1.0mg/mL.

Antibody with azide - store at 2 to 8°C. Antibody without azide - store at -20 to -80°C. Antibody is stable for 24 months. Non-hazardous.

ELISA (For coating, order antibody without BSA) ; Flow Cytometry (1-2ug/million cells) ; Immunofluorescence (1-2ug/ml) ; Western Blot (1-2ug/ml)

Mouse IgM, kappa